Qureight
Provides AI technology for lung and heart clinical trials, helping bring machine learning into study workflows for cardiopulmonary research.
Overview
Qureight is a Cambridge-based AI healthcare company developing technology to bring AI into lung and heart clinical trials. Its work is focused on cardiopulmonary studies, targeting organizations running or supporting clinical research in these disease areas. The company’s positioning centers on applying AI to specialized trial workflows rather than broad healthcare use cases. Qureight raised a $20 million Series B in July 2026, bringing total disclosed funding to $20 million across one reported round.
Funding History
Exclusive: Cambridge’s Qureight raises $20M to bring AI to lung and heart clinical trials
Frequently Asked Questions
- How much funding does AI Funding track for Qureight?
- AI Funding tracks $20M for Qureight across 1 funding round in this database.
- Who are Qureight's investors?
- Qureight's investors include Guinness Ventures, Ascension, XTX Ventures, Molten Ventures, Meltwind, and 1 others.
- What does Qureight do?
- Qureight is a Cambridge-based AI healthcare company developing technology to bring AI into lung and heart clinical trials. Its work is focused on cardiopulmonary studies, targeting organizations running or supporting clinical research in these disease areas. The company’s positioning centers on applying AI to specialized trial workflows rather than broad healthcare use cases. Qureight raised a $20 million Series B in July 2026, bringing total disclosed funding to $20 million across one reported round.
- Where is Qureight headquartered?
- Qureight is headquartered in Cambridge, United Kingdom.
Investors
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.